128 related articles for article (PubMed ID: 26622756)
1. Receptor activator of nuclear factor κB expression is a prognostic factor in human osteosarcoma.
Trieb K; Windhager R
Oncol Lett; 2015 Sep; 10(3):1813-1815. PubMed ID: 26622756
[TBL] [Abstract][Full Text] [Related]
2. Impact of RANK signalling on survival and chemotherapy response in osteosarcoma.
Bago-Horvath Z; Schmid K; Rössler F; Nagy-Bojarszky K; Funovics P; Sulzbacher I
Pathology; 2014 Aug; 46(5):411-5. PubMed ID: 24842377
[TBL] [Abstract][Full Text] [Related]
3. CD9 expression is not a prognostic factor in human osteosarcoma.
Kubista B; Erovic BM; Klinger H; Sulzbacher I; Trieb K
Cancer Lett; 2004 Jun; 209(1):105-10. PubMed ID: 15145525
[TBL] [Abstract][Full Text] [Related]
4. Role of RANK and Akt1 activation in human osteosarcoma progression: A clinicopathological study.
Zhu J; Liu Y; Zhu Y; Zeng M; Xie J; Lei P; Li K; Hu Y
Exp Ther Med; 2017 Jun; 13(6):2862-2866. PubMed ID: 28587351
[TBL] [Abstract][Full Text] [Related]
5. Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells.
Mori K; Berreur M; Blanchard F; Chevalier C; Guisle-Marsollier I; Masson M; Rédini F; Heymann D
Oncol Rep; 2007 Dec; 18(6):1365-71. PubMed ID: 17982618
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 correlates with localization but not outcome in human osteosarcoma.
Trieb K; Sulzbacher I; Kubista B
Oncol Lett; 2013 Aug; 6(2):559-561. PubMed ID: 24137369
[TBL] [Abstract][Full Text] [Related]
7. The Intrinsic and Extrinsic Implications of RANKL/RANK Signaling in Osteosarcoma: From Tumor Initiation to Lung Metastases.
Navet B; Ando K; Vargas-Franco JW; Brion R; Amiaud J; Mori K; Yagita H; Mueller CG; Verrecchia F; Dumars C; Heymann MF; Heymann D; Lézot F
Cancers (Basel); 2018 Oct; 10(11):. PubMed ID: 30355966
[No Abstract] [Full Text] [Related]
8. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage.
Komuro H; Olee T; Kühn K; Quach J; Brinson DC; Shikhman A; Valbracht J; Creighton-Achermann L; Lotz M
Arthritis Rheum; 2001 Dec; 44(12):2768-76. PubMed ID: 11762937
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.
Tabone MD; Brugières L; Piperno-Neumann S; Selva MA; Marec-Bérard P; Pacquement H; Lervat C; Corradini N; Gentet JC; Couderc R; Chevance A; Mahier-Ait Oukhatar C; Entz-Werle N; Blay JY; Le Deley MC
BMC Cancer; 2017 Jun; 17(1):419. PubMed ID: 28619014
[TBL] [Abstract][Full Text] [Related]
10. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis.
Lubberts E; Oppers-Walgreen B; Pettit AR; Van Den Bersselaar L; Joosten LA; Goldring SR; Gravallese EM; Van Den Berg WB
Arthritis Rheum; 2002 Nov; 46(11):3055-64. PubMed ID: 12428250
[TBL] [Abstract][Full Text] [Related]
11. Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling.
Golden D; Saria EA; Hansen MF
J Cell Physiol; 2015 Dec; 230(12):2951-60. PubMed ID: 25893522
[TBL] [Abstract][Full Text] [Related]
12. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
13. Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts.
Akiyama T; Dass CR; Shinoda Y; Kawano H; Tanaka S; Choong PF
J Pharm Pharmacol; 2010 Apr; 62(4):470-6. PubMed ID: 20604836
[TBL] [Abstract][Full Text] [Related]
14. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells.
Beristain AG; Narala SR; Di Grappa MA; Khokha R
J Cell Sci; 2012 Feb; 125(Pt 4):943-55. PubMed ID: 22421365
[TBL] [Abstract][Full Text] [Related]
15. RANK and RANK ligand expression in primary human osteosarcoma.
Branstetter D; Rohrbach K; Huang LY; Soriano R; Tometsko M; Blake M; Jacob AP; Dougall WC
J Bone Oncol; 2015 Sep; 4(3):59-68. PubMed ID: 27556008
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2.
Nadiminty N; Lou W; Lee SO; Mehraein-Ghomi F; Kirk JS; Conroy JM; Zhang H; Gao AC
Clin Cancer Res; 2006 Mar; 12(5):1420-30. PubMed ID: 16533764
[TBL] [Abstract][Full Text] [Related]
17. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
Vidula N; Yau C; Li J; Esserman LJ; Rugo HS
Breast Cancer Res Treat; 2017 Aug; 165(1):129-138. PubMed ID: 28577080
[TBL] [Abstract][Full Text] [Related]
19. Examination of the mechanisms of osteolysis in patients with metastatic breast cancer.
Trinkaus M; Ooi WS; Amir E; Popovic S; Kalina M; Kahn H; Singh G; Gainford MC; Clemons M
Oncol Rep; 2009 May; 21(5):1153-9. PubMed ID: 19360288
[TBL] [Abstract][Full Text] [Related]
20. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup.
Hauben EI; Weeden S; Pringle J; Van Marck EA; Hogendoorn PC
Eur J Cancer; 2002 Jun; 38(9):1218-25. PubMed ID: 12044509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
